Patients with asthma who used depemokimab tolerated treatment well while experiencing reductions in rates of clinically ...

The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps ...

In the SWIFT and ANCHOR trials, depemokimab demonstrated statistically significant reductions in nasal polyp size, obstruction, and asthma exacerbations compared to placebo. The FDA has accepted GSK’s ...

A 12-month interim analysis of the AGILE Phase III extension study confirms the long-term safety and efficacy of twice-yearly ...

A new asthma treatment, depemokimab, has shown promise in reducing exacerbations while maintaining a strong safety profile, according to findings presented at the 2025 American Academy of Allergy ...

Depemokimab has already shown its potential as a therapy for severe asthma in two other phase 3 trials – SWIFT-1 and SWIFT-2 – and GSK is in the process of preparing regulatory filings for the ...

The applications pertain to the use of depemokimab as an add-on maintenance treatment for asthma in patients 12 years and older with type 2 inflammation, and for adults with inadequately ...

A Prescription Drug User Fee Act target date of December 16, 2025 has been assigned to the application. The Food and Drug Administration (FDA) has accepted for review the Biologics License ...

A new asthma treatment, depemokimab, has shown promise in reducing exacerbations while maintaining a strong safety profile, according to findings presented at the 2025 American Academy of Allergy, ...

The applications pertain to the use of depemokimab as an add-on maintenance treatment for asthma in patients 12 years and older with type 2 inflammation, and for adults with inadequately controlled ...